Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, BLT
Riemsma, R
Tomini, F
van Asselt, T
Deshpande, S
Duffy, S
Armstrong, N
Severens, JL
Kleijnen, J
Joore, MA

Open PDF

Open link

Publication date

February 2017

DOI

10.1007/s40273-016-0445-5

Publisher

Springer Science and Business Media LLC

Journal

PharmacoEconomics

Abstract

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (see the HTA programme website for further project information [http://www.hta.ac.uk])

Extracted data

We use cookies to provide a better user experience.

Data Protection

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, BLT
Riemsma, R
Tomini, F
van Asselt, T
Deshpande, S
Duffy, S
Armstrong, N
Severens, JL
Kleijnen, J
Joore, MA

Open PDF

Open link

Publication date

February 2017

DOI

10.1007/s40273-016-0445-5

Publisher

Springer Science and Business Media LLC

Journal

PharmacoEconomics

Abstract

Extracted data

Houédé, Nadine
Beuzeboc, Philippe
Gourgou, Sophie
Tosi, Diego
Moise, Laura
Gravis, Gwenaëlle
Delva, Remy
Fléchon, Aude
Latorzeff, Igor
Ferrero, Jean-Marc
Oudard, Stéphane
Tartas, Sophie
Laguerre, Brigitte
Topart, Delphine
Roubaud, Guilhem
Agherbi, Hanane
Rebillard, Xavier
Azria, David

December 2015

International audienceAbstractBackgroundCOU-AA-301 trial has proved that abiraterone acetate (AA), a...

Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies

Michele Marchioni
Petros Sountoulides
Maida Bada
Sebastiano Rapisarda
Cosimo De Nunzio
Fabiola Raffaella Tamburro
Luigi Schips
Luca Cindolo

October 2018

Background: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemothe...

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Fizazi, Karim
Scher, Howard I.
Molina, Arturo
Logothetis, Christopher J.
Chi, Kim N.
Jones, Robert J.
Staffurth, John Nicholas
North, Scott
Vogelzang, Nicholas J.
Saad, Fred
Mainwaring, Paul
Harland, Stephen
Goodman, Oscar B.
Sternberg, Cora N.
Li, Jin Hui
Kheoh, Thian
Haqq, Christopher M.
de Bono, Johann S,

October 2012

Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostat...

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, Bram L. T.
Riemsma, Rob
Tomini, Florian
van Asselt, Thea
Deshpande, Sohan
Duffy, Steven
Armstrong, Nigel
Severens, Johan L.
Kleijnen, Jos
Joore, Manuela A.

February 2017

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactur...

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer:An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, Bram L. T.
Riemsma, Rob
Tomini, Florian
van Asselt, Thea
Deshpande, Sohan
Duffy, Steven
Armstrong, Nigel
Severens, Johan L.
Kleijnen, Jos
Joore, Manuela A.

February 2017

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactur...

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, B.L.T. (Bram)
Riemsma, R. (Rob)
Tomini, F.
Deshpande, S
Duffy, S
Armstrong, N. (Nigel)
Severens, J.L. (Hans)
Kleijnen, J.M.P. (Jos)
Joore, M.A. (Manuela)

January 2016

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactu...

Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study

Procopio G.
Chiuri V. E.
Giordano M.
Mantini G.
Maisano R.
Bordonaro R.
Calvani N.
Facchini G.
De Placido S.
Airoldi M.
Sbrana A.
Gasparro D.
Ludovico G. M.
Guglielmini P.
Naglieri E.
Fagnani D.
Aglietta M.
Schips L.
Beccaglia P.
Sciarra A.
Livi L.
Santini D.

January 2020

Background: Real-world data on chemotherapy-naïve patients with metastatic castration-resistant pros...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter real life study

Cindolo, Luca
Natoli, Clara
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Micali, Salvatore
Rizzo, Mino
Bianchi, Giampaolo
Martorana, Eugenio
Scarcia, Marcello
Ludovico, Giuseppe Mario
Bove, Pierluigi
Laudisi, Anastasia
Selvaggio, Oscar
Carrieri, Giuseppe
Bada, Maida
Castellan, Pietro
Boccasile, Stefano
Ditonno, Pasquale
Chiodini, Paolo
Verze, Paolo
Mirone, Vincenzo
Schips, Luigi

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. An Italian multicenter real life study

Cindolo L.
Natoli C.
De Nunzio C.
De Tursi M.
Valeriani M.
Giacinti S.
Micali S.
Rizzo M.
Bianchi G.
Martorana E.
Scarcia M.
Ludovico G. M.
Bove P.
Laudisi A.
Selvaggio O.
Carrieri G.
Bada M.
Castellan P.
Boccasile S.
Ditonno P.
Chiodini P.
Verze P.
Mirone V.
Schips L.

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter "real life" study

Cindolo L.
Natoli C.
De Nunzio C.
De Tursi M.
Valeriani M.
Giacinti S.
Micali S.
Rizzo M.
Bianchi G.
Martorana E.
Scarcia M.
Ludovico G. M.
Bove P.
Laudisi A.
Selvaggio O.
Carrieri G.
Bada M.
Castellan P.
Boccasile S.
Ditonno P.
Chiodini P.
Verze P.
Mirone V.
Schips L.

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal"

Ramaekers, BLT
Riemsma, R
Tomini, F
van Asselt, T
Deshpande, S
Duffy, S
Armstrong, N
Severens, JL
Kleijnen, J
Joore, MA

June 2017

This project was funded by the National Institute for Health Research (NIHR) Health Technology Asses...

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Houédé, Nadine
Beuzeboc, Philippe
Gourgou, Sophie
Tosi, Diego
Moise, Laura
Gravis, Gwenaëlle
Delva, Remy
Fléchon, Aude
Latorzeff, Igor
Ferrero, Jean-Marc
Oudard, Stéphane
Tartas, Sophie
Laguerre, Brigitte
Topart, Delphine
Roubaud, Guilhem
Agherbi, Hanane
Rebillard, Xavier
Azria, David

December 2015

International audienceAbstractBackgroundCOU-AA-301 trial has proved that abiraterone acetate (AA), a...

Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies

Michele Marchioni
Petros Sountoulides
Maida Bada
Sebastiano Rapisarda
Cosimo De Nunzio
Fabiola Raffaella Tamburro
Luigi Schips
Luca Cindolo

October 2018

Background: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemothe...

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Fizazi, Karim
Scher, Howard I.
Molina, Arturo
Logothetis, Christopher J.
Chi, Kim N.
Jones, Robert J.
Staffurth, John Nicholas
North, Scott
Vogelzang, Nicholas J.
Saad, Fred
Mainwaring, Paul
Harland, Stephen
Goodman, Oscar B.
Sternberg, Cora N.
Li, Jin Hui
Kheoh, Thian
Haqq, Christopher M.
de Bono, Johann S,

October 2012

Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostat...

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, Bram L. T.
Riemsma, Rob
Tomini, Florian
van Asselt, Thea
Deshpande, Sohan
Duffy, Steven
Armstrong, Nigel
Severens, Johan L.
Kleijnen, Jos
Joore, Manuela A.

February 2017

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactur...

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer:An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, Bram L. T.
Riemsma, Rob
Tomini, Florian
van Asselt, Thea
Deshpande, Sohan
Duffy, Steven
Armstrong, Nigel
Severens, Johan L.
Kleijnen, Jos
Joore, Manuela A.

February 2017

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactur...

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Ramaekers, B.L.T. (Bram)
Riemsma, R. (Rob)
Tomini, F.
Deshpande, S
Duffy, S
Armstrong, N. (Nigel)
Severens, J.L. (Hans)
Kleijnen, J.M.P. (Jos)
Joore, M.A. (Manuela)

January 2016

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufactu...

Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study

Procopio G.
Chiuri V. E.
Giordano M.
Mantini G.
Maisano R.
Bordonaro R.
Calvani N.
Facchini G.
De Placido S.
Airoldi M.
Sbrana A.
Gasparro D.
Ludovico G. M.
Guglielmini P.
Naglieri E.
Fagnani D.
Aglietta M.
Schips L.
Beccaglia P.
Sciarra A.
Livi L.
Santini D.

January 2020

Background: Real-world data on chemotherapy-naïve patients with metastatic castration-resistant pros...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter real life study

Cindolo, Luca
Natoli, Clara
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Micali, Salvatore
Rizzo, Mino
Bianchi, Giampaolo
Martorana, Eugenio
Scarcia, Marcello
Ludovico, Giuseppe Mario
Bove, Pierluigi
Laudisi, Anastasia
Selvaggio, Oscar
Carrieri, Giuseppe
Bada, Maida
Castellan, Pietro
Boccasile, Stefano
Ditonno, Pasquale
Chiodini, Paolo
Verze, Paolo
Mirone, Vincenzo
Schips, Luigi

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. An Italian multicenter real life study

Cindolo L.
Natoli C.
De Nunzio C.
De Tursi M.
Valeriani M.
Giacinti S.
Micali S.
Rizzo M.
Bianchi G.
Martorana E.
Scarcia M.
Ludovico G. M.
Bove P.
Laudisi A.
Selvaggio O.
Carrieri G.
Bada M.
Castellan P.
Boccasile S.
Ditonno P.
Chiodini P.
Verze P.
Mirone V.
Schips L.

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter "real life" study

Cindolo L.
Natoli C.
De Nunzio C.
De Tursi M.
Valeriani M.
Giacinti S.
Micali S.
Rizzo M.
Bianchi G.
Martorana E.
Scarcia M.
Ludovico G. M.
Bove P.
Laudisi A.
Selvaggio O.
Carrieri G.
Bada M.
Castellan P.
Boccasile S.
Ditonno P.
Chiodini P.
Verze P.
Mirone V.
Schips L.

January 2017

Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the real life clinica...

Ramaekers, BLT
Riemsma, R
Tomini, F
van Asselt, T
Deshpande, S
Duffy, S
Armstrong, N
Severens, JL
Kleijnen, J
Joore, MA

June 2017

This project was funded by the National Institute for Health Research (NIHR) Health Technology Asses...

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Houédé, Nadine
Beuzeboc, Philippe
Gourgou, Sophie
Tosi, Diego
Moise, Laura
Gravis, Gwenaëlle
Delva, Remy
Fléchon, Aude
Latorzeff, Igor
Ferrero, Jean-Marc
Oudard, Stéphane
Tartas, Sophie
Laguerre, Brigitte
Topart, Delphine
Roubaud, Guilhem
Agherbi, Hanane
Rebillard, Xavier
Azria, David

December 2015

International audienceAbstractBackgroundCOU-AA-301 trial has proved that abiraterone acetate (AA), a...

Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies

Michele Marchioni
Petros Sountoulides
Maida Bada
Sebastiano Rapisarda
Cosimo De Nunzio
Fabiola Raffaella Tamburro
Luigi Schips
Luca Cindolo

October 2018

Background: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemothe...

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Fizazi, Karim
Scher, Howard I.
Molina, Arturo
Logothetis, Christopher J.
Chi, Kim N.
Jones, Robert J.
Staffurth, John Nicholas
North, Scott
Vogelzang, Nicholas J.
Saad, Fred
Mainwaring, Paul
Harland, Stephen
Goodman, Oscar B.
Sternberg, Cora N.
Li, Jin Hui
Kheoh, Thian
Haqq, Christopher M.
de Bono, Johann S,

October 2012

Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostat...

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Abstract

Extracted data

Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Abstract

Extracted data

Related items

Related items